• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    1. Claims for the contracting states : CH DE GB W NL SE Compound having the formula see diagramm : EP0017543,P6,F4 both its enantiomers and the racemate, their salts with physiologically acceptable bases, inorganic cations and amines, and their salts with physiologically acceptable inorganic or organic acids and their alkyl esters. 1. Claims for the contracting state : AT Process for the preparation of a compound having the formula see diagramm : EP0017543,P7,F2 both its enantiomers and the racemate, their salts with physiologically acceptable bases, inorganic cations and amines, and their salts with physiologically acceptable inorganic or organic acids and their alkyl esters, characterized in that benzoic acid or a reactive equivalent thereof, such as the corresponding acid chloride, ester or aldehyde is reacted, with a compound of the formula see diagramm : EP0017543,P7,F3 or an equivalent of said compound, such as the corresponding disulfide, and optionally converting the resulting acid to a salt or an ester.
    公开号:SU910120A3
    申请号:SU802901454
    申请日:1980-04-01
    公开日:1982-02-28
    发明作者:Лепан Марсель；Бессен Пьер；Боннэ Жаклин
    申请人:Альбер Роллан С.А. (Фирма)；
    IPC主号:
    专利说明:

    I, which is that a benzoic acid or its reactive equivalent, such as an acid chloride or ester, or benzaldehyde, is reacted with a compound of the formula
    four
    equivalent compound disulfide
    , w.
    If
    SH
    jLcH-COOH CHi or an equivalent of this compound, for example, with its disulfide derivative, and the target acid is isolated in the form of its enantiomers or racemic active compounds, or its salts with amines or metals, or its salts with mineral or organic acids, or its alkyl esters. . The racemic acids of the formula D are obtained by reacting, nooch-CHOOC-CH-i CH3 with benzoic acid or its derivative such as beozoyl chloride, benzoyl ester or benzoic aldehyde, and the reaction with benzoyl chloride leads to the best yield. During the action of the acid chloride on the aminothiol of formula I, which proceeds preferably in the presence of an inorganic or organic base, intermediate compounds are formed
    These compounds of formulas Y and VI are not purified, but THEIR mixture is cyclized either by heat or by acids or bases.
    Both acid enantiomers of the formula G can be separated using the salt of the corresponding acid with a chiral amine, and in particular each of the two enantiomers of 2-phenyl-ethylamine. These salts recrystallize the dp separation of both diastereoisomers.
    Salts of acids of formula I can be obtained by exposing the stoichiometric amount of the chosen acid or base to the acids of formula I dissolved in an alcohol, ketone or aliphatic ether.
    The esters of acids of the formula I can be obtained by the action of an ether or a haloalkane on the acid forms, ly I or on one of their reactive derivatives.
    Example 1. Preparation of 2- (2-amino-6-benothiazolyl) propionic acid.
    权利要求:
    Claims (2)
    [1]
    24.7 g of 2- {4-aminophenyl) - propionic acid is dissolved in AOO ml of acetic acid, then 22.8 g of ammonium thiocyanate is added. At 15 ° C, 24 g of bromine dissolved in 60 ml of acetic acid are added dropwise to this solution, the mixture is allowed to rise to room temperature and stirring is continued for several hours. Then the solvent is removed under reduced pressure and the residual oil is suspended in The aqueous acidic solution is removed and the pH of the aqueous phase is adjusted to 4.5 using sodium hydroxide solution. The resulting precipitate is isolated by filtration and recrystallized from methanol or 5 ethanol to give 26 g of pure 2- (2-amino-6-benzothiazolyl) propionic acid, m.p. . Preparation of 2- (2-phenyl-6-benlothiaz lil) -propionic acid using benzoyl chloride. The mixture is refluxed until ammonia is released, a solution of 45 g of 2- (2-amino-6-benzothiazolyl) propionic acid in 200 ml of a 40% aqueous solution of sodium hydroxide containing shsh do not contain 40 g of anhydrous sodium sulfide. Approximately 50 ml of water are introduced into the solution and, at 10 ° C, 70 g of benzoyl chloride in the form of a 10% solution in a water-immiscible solvent, such as benzene, are slowly and vigorously stirred. At the end of the addition, the reaction mixture is left to warm up to room temperature and stirring is continued for several hours until the organic phase is separated and the aqueous phase is acidified until the aqueous concentrated hydrochloric acid solution is added. The precipitate formed contained benzoic acid, non-cyclized derivatives of type Y and Y1, and sometimes even the target benzothiazole. This mixture is cyclized, for example, by heating a solid resinous substance at 120 ° C for several hours while still in an acidic medium as follows. The solid is dissolved in 1 water containing 70 ml of a 40% aqueous solution of sodium hydroxide, the solution is filtered through vegetable soot, then drank dropwise into an approximately 2N aqueous solution of hydrochloric acid, maintained at about 500 s, the precipitate is separated filtering off at this site. Then, 45 g of the target acid, obtained in the manner described above, will be recrystallized from aqueous (2/1) iso-propanol or from a mixture of butanone-2 / cyclohexane (1/2) to obtain Zbg of a melting cryous product, measured at 160 ° C. Depending on the recrystallization solvents and the precipitation rate, the acid is in various crystalline forms, sometimes with very close melting points, but the infrared spectra of which in the solid phase do not match. The cyclization can also be carried out in basic medium, but then the resulting solid, washed extensively with water, is dissolved in 350 ml of a 95% aqueous solution of ethanol containing 25 g of potassium hydroxide, then after several hours of heating, acidified, removed ethanol and poured about 1 liter of water. The precipitated target acid that is formed is isolated and recrystallized as described previously. Example 2. Obtaining 2- (2-phenyl-6-benzothiazolyl) -propionic acid using benzaldehyde. 22 g of 2- (2-amino-6-benzothiazolyl propionic acid is dissolved in 100 ml of concentrated pacTSdpa sodium hydroxide and the mixture is boiled for 1 h under reflux (the cessation of release of ammonia. At room temperature the pH is brought to 4.5 by adding hydrochloric acid solution and the precipitate is filtered off. Thus, 16 g of precipitate is isolated with a melting point close to 154 ° C. This solid and 8 g of benzaldehyde are dissolved in 100 mp of pyridine and the mixture is heated under reflux 5 hours. Then the solvent is removed under reduced pressure. The sediment is dissolved in too ml of ethanol, 200 ml of ferric chloride is added and the solution is refluxed for 2 hours under reflux. After cooling, the precipitate is cooled by dissolving in an aqueous basic solution before crystallization from a mixture of butanone-2 and cyclohexane ( 1/2) The desired product is obtained in its pure form with a yield of 40%. Example 3. Hygroscopic 2- (2-phenyl-6-benzothiazolyl-propionic acid sodium salt is obtained by exposure to 0.55 g of sodium hydroxide per 3.7 g of acid, dissolved in dissolved m.p. . This 100 ml of methanol salt is soluble in water. Example 4. The pyrrolidine salt of 2- (2-fensh-1 -6-benzothiazolyl) propionic acid is prepared by the action of 1 g of amine per 4 g of acid, dissolved in methanol. The salt melts: 7 at. This salt is soluble in water. Example 5. Methanesulfonate 2- {2-phenyl-6-benzothiazolyl-propionic acid is obtained by exposure to O, I mol of sulfonic acid on O, 1 mol of acid dissolved in 500 ml of acetone, T.Sh1. 182 C. Example 6. 2- (2-phenyl-6-benzothiazolyl) -propionic acid hydrochloride is prepared by exposing the ki to hydrogen dissolved in benzene to hydrogen chloride gas. It is set at 160 ° C with decomposition. Example 7. Preparation of methyl24 2-phenyl-6-benzothiazolyl) propionate. 6 g of 2- (2-phenyl-6-beisothiazolyl) propionic acid is dissolved in 100 Mj (anhydrous methanol and dissolved under reflux 6 after adding a few drops of concentrated sulfuric acid. The solution is concentrated by half and the ether is precipitated by adding one volume of ice Thus, 5 g of ether is obtained, which is melted by Example 8. Isolation of the 2 enantiomers of 2- (2-phenyl-6-benzothiaz lyl) -propionic acid from the) racemic mixture. Programma-enantiomer (as a solution in dimethylformamide). A salt of the acid is prepared with a levorotatory oL-phenylethylamine in butanol-2. By adding 19 g of amine, dissolved in 50 ml of butanone-2, to a solution of 50 g of acid in 500 ml of butanone-2, 51 g of salt is precipitated. It is recrystallized six times from the minimum amount of butanone-2, yielding 10 g of salt with a specific rotational ability in methanol (g / 100 ml) -22.5. Acid is isolated by adding hydrochloric acid to an aqueous solution of this amine salt. The precipitated precipitate is recrystallized several times from a mixture of isopropanol and water (2 / l) to obtain a 35% right programer: enantiomer. M.p. 179 ° C. Levorotatory enantiomer (as a solution in dimethylformamide). The solvents of recrystallization of the chiral salt are evaporated and the acid, slightly enriched in the levorotating enantiomer, is isolated from its salt. Thus, 25-g of acids 08 are obtained from which 28 g of the salt is obtained by adding 10.3 g of the programer about α-phenylethylamine to the acid dissolved in 540 ml of butanone.
    [2]
    2. After three recrystallisations from butanone-2, the isolated salt has a following, rotary capacity) 23 (with 2 g / 100 ml in metalol. The acid is then separated from its salt and recrystallized several times in succession from isopropanol / water mixtures (2 /) and butanone-2 / cyclohexane (l / 2) to obtain 25% of a levorotatory isomer with optical purity close to 98%. d 81 ° in dimethylformamide (, 1 g / mp) and so on, 175 ° C, Compounds Formulas G and their derivatives are inhibitors of prostaglandin biosynthesis, and have analgesic properties in inhibitory doses. They also possess anti-aggregating platelet activity and protect against cardiovascular effects from shock with endotoxin. Their toxicity is low (oral mice have more than 1000 mg / kg orally). Spectacular doses, measured in various experiments, are insignificant, the therapeutic index of these compounds is excellent. (excellent), which allows them to be used in human therapy. The analgesic activity of the compounds of formula I is emphasized in the convulsions test in mice using phenylbenzbhinon. Thus, the acid of formula I (racemic) in this test has ED CQ (3–3 mg / kg orally). This analgesic activity is prolonged over time, with a dose of 12.5 mg / kg of this compound still causing analgesia 42%, 24 hours after its administration. In addition, the compounds of the formula D reduce platelet aggregation caused in vitro by ADP on plasma in a rat enriched with platelets. Thus, sodium 2- 2-phenyl-6-benzothiazoyl-propionate is active at a concentration 10 times weaker than acetylsalicylic acid. The activity of compounds of the formula T in relation to the biosynthesis of prostaglandins is expressed in its effect, against the toxicity of arachidonic acid, the precursor of this biosynthesis. Thus, compounds of formula I, administered at a dose of 0., 5 mg / kg orally, 9 cause a decrease in mortality in mice that received a lethal dose of arachidonic acid .. The intravenously soluble salts of compounds of formula I and, especially, sodium salt, are active in the same doses. The degrading acid enantiomer (Example 8} has an activity comparable to that of a racemate (Example 1), and higher than the activity of its left-handed homolog. Finally, the compounds of formula 1, administered intravenously at a dose of 1 mg / k, show a protective effect in in case of an anesthetized dog, against cardiovascular effects from shock with Escherichia endotoxin. The compounds of formula I can be administered in various forms to human, oral, rectal or parenteral, B effective and non-toxic doses for the treatment of pain, hyperthermia, dysmenorrhea, shock conditions or other diseases in which a reduction in platelet aggregation is an important factor. Once up to .x depends on the form of administration and the chosen compound as the active principle of the drug. Solutions for parenteral or intravenous administration are preferably prepared with aqueous diluents and the active principle is in soluble form and, for example, in the form of a salt of an alkali metal cation. For oral administration, the compounds of the invention may be administered in gelatinous capsules with a medicine or mixed Search with conventional experimenters to make pills, capsules, or tablets that release directly the active I.T1I ingredients that are soluble in the intestines. The daily dosage for an adult, except in a special case, is 20 mg 1 g in one or several doses. Isobenzal formula Method for preparing 2- (2-phenyl-6-benzothiazolyl-propionic acid of the formula noosc in the form of its enantiomers or racemic active compounds, or its salts with amines or metals, or its salts with mineral or organic acids, or its alkyl esters characterized in that benzoic acid or its reactive equivalent, for example an acid chloride or ester, or benzaldehyde, is reacted with a compound of the formula HOOC-CH or an equivalent of this compound, for example its disulfide one derivative, and the target acid is identified as its enantiomers or racemic active compounds, or its salts with amines or metals, or its salts with mineral or organic acids, or its alkyl esters. Sources of information taken into account in examination 1 USSR Author's Certificate No. 732259, class C 07 D 277/66, 1977.
    类似技术:
    公开号 | 公开日 | 专利标题
    FI87216B|1992-08-31|METHOD OF ALAMINATION OF METHYL ALPHA-5- | THIENOPYRIDYL) - | ACETATE.
    SU820659A3|1981-04-07|Method of preparing 4-amino-5-alkylsulfonyl-o-anisamide derivatives,their salts,oxides,left-and right-rotational isomers |
    SU910120A3|1982-02-28|Process for producing 2-| propionic acid in the form of its enantiomorphs or racemically active compounds, or its salts with amines or metals, or its salts with mineral or organic acids, or its alkyl esters
    KR960007602B1|1996-06-07|Phenoxyalkylcarboxylic acid derivatives and the preparation process
    CA2437215A1|2002-08-15|Dihydropyrazolopyridine compounds and pharmaceutical use thereof
    Kipnis et al.1949|2-Acyloxyacetylthiophenes
    JPH0517459A|1993-01-26|New 2-substituted-4-| thiazoles
    US3337576A|1967-08-22|Arylthioalkyltetrazoles
    US4659728A|1987-04-21|Hydroxy substituted 4,5-diphenyl-2-oxazole propanoic acid
    US4399284A|1983-08-16|Process for the optical resolution of mixtures of D- and L-2-|-propionic acids
    US3466372A|1969-09-09|Treatment of inflammation with 4-phenyl - alpha - methyl - phenyl acetic acid,its salts,esters or amide derivatives
    US5321154A|1994-06-14|Optical resolution of |-2-|-propionic acid
    US4906757A|1990-03-06|Process for the preparation of dextrorotatory 3-|-1H,3H-pyrrolo [1,2-c]-7-thiazolecarboxylic acid
    US4116972A|1978-09-26|Anti-inflammatory 1-oxo-isoindoline derivatives and processes for their preparation
    CS216205B2|1982-10-29|Method of making the derivatives of the 1,4-diphenylpyrazole
    GB2204579A|1988-11-16|Optically active oxo-isoindolinyl derivatives
    US4562287A|1985-12-31|2-|-4-hexenoic acid and derivatives thereof having anti-inflammatory activity
    CA1088078A|1980-10-21|6,11-dihydro-11-oxodibenz [b,e] oxepinalkanoic acids and esters thereof
    US4324801A|1982-04-13|Phenylguanidine acetylsalicylate compounds, process for production thereof, and pharmaceutical composition thereof
    SU1053750A3|1983-11-07|Process for preparing derivatives of isoxazole
    KR850001224B1|1985-08-23|Process for preparing 2,4-dioxacyclohexanone derivatives
    US5120851A|1992-06-09|Preparation process for making water-soluble lysine salts of |2-|-alpha-methyl-5-benzoxazole acetic acid
    US4829077A|1989-05-09|Benzopyran[4,3-d]-thiazole-derivatives with anti-allergic, anti-anaphylactic and anti-arithritic activity and compositions containing them
    KR790001825B1|1979-12-22|Process for preparing stilbene derivatives
    IL23268A|1969-02-27|Anti-inflammatory compositions containing 4-phenyl-alpha-methyl-phenylacetic acid
    同族专利:
    公开号 | 公开日
    BE882270A|1980-09-17|
    JPS55133367A|1980-10-17|
    GR67195B|1981-06-24|
    PL123701B1|1982-11-30|
    AR227884A1|1982-12-30|
    MA18772A1|1980-10-01|
    HU178851B|1982-07-28|
    AU5686480A|1980-10-09|
    FR2453163B1|1982-07-02|
    ES8204989A1|1982-06-01|
    AU530911B2|1983-08-04|
    ES490797A0|1981-11-01|
    PH15451A|1983-01-18|
    IL59655D0|1980-06-30|
    FR2453163A1|1980-10-31|
    DD151448A5|1981-10-21|
    EP0017543A1|1980-10-15|
    PT71035A|1980-04-01|
    ES8200098A1|1981-11-01|
    DK134880A|1980-10-04|
    ES498313A0|1982-06-01|
    DE3065004D1|1983-11-03|
    AT4807T|1983-10-15|
    OA06504A|1981-07-31|
    IL59655A|1983-05-15|
    NO800946L|1980-10-06|
    YU80780A|1983-02-28|
    ZA801574B|1981-03-25|
    EP0017543B1|1983-09-28|
    NZ193337A|1982-12-07|
    CA1144556A|1983-04-12|
    FI801023A|1980-10-04|
    IT8048308D0|1980-04-01|
    PL223191A1|1981-01-30|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DE2145178C3|1970-09-11|1975-12-11|Tokyo Tanabe Co., Ltd., Tokio|2-phenyl-5- or -6-benzothiazolylacetic acid compounds|
    US3895028A|1972-09-12|1975-07-15|Tokyo Tanabe Co|Alpha-propionic acid|WO2003066546A1|2002-02-05|2003-08-14|Sumitomo Chemical Company, Limited|Process for producing biaryl compound|
    NZ604716A|2010-07-02|2014-12-24|Gilead Sciences Inc|2-quinolinyl-acetic acid derivatives as hiv antiviral compounds|
    CA2802308C|2010-07-02|2018-08-28|Lianhong Xu|Napht-2-ylacetic acid derivatives to treat aids|
    CA2833377C|2011-04-21|2019-02-12|Gilead Sciences, Inc.|Benzothiazole compounds and their pharmaceutical use|
    WO2013103738A1|2012-01-04|2013-07-11|Gilead Sciences, Inc.|Napthalene acetic acid derivatives against hiv infection|
    US9376392B2|2012-01-04|2016-06-28|Gilead Sciences, Inc.|2--2- acetic acid derivatives for treating AIDS|
    US8987250B2|2012-04-20|2015-03-24|Gilead Sciences, Inc.|Therapeutic compounds|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    FR7908303A|FR2453163B1|1979-04-03|1979-04-03|
    [返回顶部]